Evidence map›Paper›PMID 38508637›Full record

ArticleBMJ open2024

Implementation of an antibiotic resistance surveillance tool in Madagascar, the TSARA project: a prospective, observational, multicentre, hospital-based study protocol.

Christelle Elias, Mathieu Raad, Saida Rasoanandrasana, Antso Hasina Raherinandrasana, Volatiana Andriananja, Mihaja Raberahona, Catrin E Moore, Mamy Randria, Laurent Raskine, Philippe Vanhems and 1 more

Abstract readClinical Trial Protocol
In one paragraph

Article in BMJ open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Generating Actionable Data From Antimicrobial Resistance Surveillance: Insights From the Fleming Fund's International Experience.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Christelle EliasService Hygiène et Epidémiologie, Hospices Civils de Lyon, Lyon, France christelle.elias@chu-lyon.fr.ORCID 0000-0002-6962-161X
Mathieu RaadDirection des Opérations Internationales, Fondation Mérieux, Lyon, France.
Saida RasoanandrasanaService de Biologie, Hôpital Befelatanana, Antananarivo, Madagascar.
Antso Hasina RaherinandrasanaDépartement de Santé Publique, Faculté de Médecine de l'Université d'Antananarivo, Antananarivo, Madagascar.
Volatiana AndriananjaService des Maladies Infectieuses, Hôpital Befelatanana, Antananarivo, Madagascar.
Mihaja RaberahonaService des Maladies Infectieuses, Hôpital Befelatanana, Antananarivo, Madagascar.ORCID 0000-0001-8857-5834
Catrin E MooreCentre for Neonatal and Paediatric Infection, St. George's, University of London, London, UK.
Mamy RandriaService de Biologie, Hôpital Befelatanana, Antananarivo, Madagascar.
Laurent RaskineDirection des Opérations Internationales, Fondation Mérieux, Lyon, France.
Philippe VanhemsService Hygiène et Epidémiologie, Hospices Civils de Lyon, Lyon, France.
François-Xavier BabinDirection des Opérations Internationales, Fondation Mérieux, Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAntimicrobial resistance (AMR) has become a significant public health threat. Without any interventions, it has been modelled that AMR will account for an estimated 10 million deaths annually by 2050, this mainly affects low/middle-income countries. AMR has a systemic negative perspective affecting the overall healthcare system down to the patient's personal outcome. In response to this issue, the WHO urged countries to provide antimicrobial stewardship programmes (ASPs). ASPs in hospitals are a vital component of national action plans for AMR, and have been shown to significantly reduce AMR, in particular in low-income countries such as Madagascar.As part of an ASP, AMR surveillance provides essential information needed to guide medical practice. We developed an AMR surveillance tool-Technique de Surveillance Actualisée de la Résistance aux Antimicrobiens (TSARA)-with the support of the Mérieux Foundation. TSARA combines bacteriological and clinical information to provide a better understanding of the scope and the effects of AMR in Madagascar, where no such surveillance tool exists. METHODS AND ANALYSIS: A prospective, observational, hospital-based study was carried out for data collection using a standardised data collection tool, called TSARA deployed in 2023 in 10 hospitals in Madagascar participating in the national Malagasy laboratory network (Réseau des Laboratoires à Madagascar (RESAMAD)). Any hospitalised patient where the clinician decided to take a bacterial sample is included. As a prospective study, individual isolate-level data and antimicrobial susceptibility information on pathogens were collected routinely from the bacteriology laboratory and compiled with clinical information retrieved from face-to-face interviews with the patient and completed using medical records where necessary. Analysis of the local ecology, resistance rates and antibiotic prescription patterns were collected. ETHICS AND DISSEMINATION: This protocol obtained ethical approval from the Malagasy Ethical Committee n°07-MSANP/SG/AGMED/CNPV/CERBM on 24 January 2023. Findings generated were shared with national health stakeholders, microbiologists, members of the RESAMAD network and the Malagasy academic society of infectious diseases.

Indexed as

Anti-Bacterial AgentsHospitalsDrug Resistance, BacterialDrug Resistance, MicrobialHumansMadagascarMulticenter Studies as TopicObservational Studies as TopicProspective StudiesAnti-Bacterial AgentsBACTERIOLOGYDiagnostic microbiologyEpidemiologyProtocols & guidelines

Identifiers

PMID38508637
PMCPMC10953040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.